Business Wire

Technology Innovation Institute’s Secure Systems Research Centre in Abu Dhabi Announces Launch of First Motion Capture Facility Outside United States

8.9.2021 15:29:00 EEST | Business Wire | Press release

Share

Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today announced that its Secure Systems Research Centre (SSRC) is pioneering a first-in-the-region Motion Capture (MOCAP) facility. Outside of the United States, SSRC’s unique MOCAP facility at its Masdar City premises, will enable the testing of Unmanned Aerial Systems (UAS) or drones in an augmented reality (AR) or mixed reality environment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210908005700/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Dr Shreekant (Ticky) Thakkar, Chief Researcher, Secure Systems Research Centre, Technology Innovation Institute (Photo: AETOSWire)

The MOCAP facility will allow SSRC to simulate flying through the city of Abu Dhabi and enable high-precision ground truth to conduct sophisticated experiments as well as virtual, augmented and mixed reality testing. The ability to simulate virtual camera images and sensors facilitates testing in environments that are too large, too dangerous, or too time consuming to construct in reality.

The high-quality motion capture system proposed for Abu Dhabi will be able to conduct passive or active tracking and enhance the communication, navigation, command, and control capabilities achieved to date. SSRC is shaping this facility in line with its ongoing collaboration with US-based Purdue University that holds the distinction for the largest indoor motion capture facility in the world.

Speaking on the breakthrough facility that will allow the modelling and operation of a cloud-based secure autonomous system of drones - as opposed to just autonomous drones - in this environment, Dr Shreekant (Ticky) Thakkar, Chief Researcher, SSRC, said: “This is a start – an ambitious one – and we are confident we will be able to arrive at technologies that could limit malicious cyber-attacks as our reliance on drones continues to increase every day. They are integral to life today – from delivering valuable organs at a hospital to conducting surveillance of high-security zones, or dispersing seeds over a field or even completing grocery deliveries.

“This unique testing facility will be leveraged by various lab groups and allow us to conduct experiments on a broad range of Unmanned Aerial Systems of various sizes while the state-of-the-art high-resolution cameras track small objects in the surrounding environment. Our aim at SSRC is to develop breakthrough security solutions to safeguard systems that may be vulnerable, such as unsecure drone systems which may pose various threats to organisational or even individual privacy and safety. Therefore, it’s essential to make drone platforms more resilient and secure.”

On the construction of the new facility, James Goppert, Managing Director of the Purdue UAS Research and Test Facility said: “Autonomous drones are already playing a key part in package delivery and infrastructure inspection. As smart cities evolve, it will be critical to ensure the safe operation of drones in an urban setting. This facility is particularly suited to the task of bringing algorithms for the security of drones from simulation to real world application by allowing a gradual transition of scenario elements from pure simulation, to virtual, to real-world.”

The testing facility will be used by both the Secure Systems Research Centre and TII’s Autonomous Robotics Research Centre to carry out experiments on a range of vehicles. As a shared space, the Motion Capture facility can accommodate micro UAS weighing less than 10 g to large UAS that are as heavy as 1,000 kg and factor in different types of UAS from multirotor to helicopters to vertical takeoff and landing vehicles (VTOLs) to fixed wing craft.

For information on Technology Innovation Institute, visit www.tii.ae

For information on Secure Systems Research Centre, visit https://securesystems.tii.ae/

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Technology Innovation Institute
Hanz Valbuena
comms@atrc.ae

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

DCX builds coolant chemistry control into its 8 MW Facility Distribution Unit19.10.2026 15:01:00 EEST | Press release

Today DCX Liquid Cooling Systems announced worldwide’s first CDU system with built-in coolant control and treatment system. DCX integrated this coolant quality feature into it’s Facility Coolant Distribution Units: a family of 5-8 MW capable hyperscale-class coolant Distribution Units. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014488003/en/ DCX announces the world’s first CDU with built-in coolant quality control and treatment - a new safety standard for hall-scale Liquid Cooling in critical AI infrastructure. The FDU monitors the chemistry of its coolant continuously and corrects it automatically with integrated electronic dosing pumps, supplying inhibitors, biocides and PH control additives. Hyper scale datacenters require new type of cooling solutions. In today’s liquid-cooled data centers, coolant quality and water treatment is becoming a rising issue. Left unmanaged, chemistry drift quietly takes away cooling pe

STARTEEPO Sends Letter to Xerox Board in Advance of Third-Quarter Earnings19.10.2026 15:00:00 EEST | Press release

STARTEEPO SICAV a.s. (“STARTEEPO”), which beneficially owns 7.34% of Xerox Holdings Corporation (“Xerox” or the “Company”) (NASDAQ: XRX) in stocks and options, today issued the following letter to the Xerox Board of Directors (the “Board”): October 19, 2026 The Board of Directors Xerox Holdings Corp. 401 Merritt 7 Norwalk, CT 06851 Dear Members of the Board: Our open letter to the Board in early September helped spark a lively conversation about the future of this iconic company among investors and throughout the print industry. Despite these efforts, Xerox’s share price still does not reflect the significant value we see in the Company, a gap recently confirmed by Citi’s downgrade of Xerox stock to reflect the challenge of executing in “a structurally challenged print market.” Since our September letter, we’ve continued to actively engage with Xerox, including at the recent PRINTING United Expo in Las Vegas, and our conversations have been encouraging. We greatly appreciate the willin

BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 202619.10.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid. Presentations will highlight an accelerating pipeline of differentiated targeted therapies, alongside a broad body of evidence for TEVIMBRA® (tislelizumab), including a late-breaking rapid oral presentation on TEVIMBRA in combination with ZIIHERA® (zanidatamab) in HER2+ gastroesophageal adenocarcinoma (GEA). Priority pipeline data include an oral proffered paper presentation on BeOne’s GPC3x4-1BB bispecific antibody, currently being studied in hepatocellular carcinoma (HCC) and first-in-human data for two investigational lung cancer assets, a CEA targeting antibody-drug conjugate (ADC), in CEA-expressing non-small cell lung cancer (NSCLC), and a brain-penetrant PRMT5 inhibitor in MTAP-deleted tumors, inclu

The Data Center Marketplace Is Booming, Inaugural Data Center World Europe Unites Data Center and Energy Decision-Makers and Experts in Vienna19.10.2026 13:00:00 EEST | Press release

Last week, Data Center World Europe, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators over three days at VIECON – Vienna Congress & Convention Center in Vienna, Austria. It was co-located with the leading global network infrastructure event Network X, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators. Tara Gibb, Senior Director, Data Center World Europe said, “The conference tackled the industry’s most urgent challenge: transforming Europe's data centre energy landscape. We brought together leaders from across the data ce

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO ® (vedolizumab) Prolongs Time to First Disease-Related Complication19.10.2026 12:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (UC)-related complication (hazard ratio 0.33 [95% confidence interval 0.17-0.67]; P=0.0014), reducing UC complication risk by nearly 70 percent. VERDICT, a Phase 4 ENTYVIO clinical trial, provides the first prospective, randomized evidence that disease clearance is an achievable and clinically relevant target in the treatment of moderate to severe ulcerative colitis.1 Results were presented during late-breaker and poster sessions at United European Gastroenterology (UEG) Week 2026 and published in the United European Gastroenterology Journal. “There has been increasing conversation about whether achieving deeper levels of remission – addressing both visible and microscopic inflammation

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye